SEK 2.68
(21.82%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | - SEK | -100.0% |
2022 | 807.93 Thousand SEK | -53.55% |
2021 | 1.73 Million SEK | 65.71% |
2020 | 1.04 Million SEK | 0.0% |
2019 | - SEK | 0.0% |
2018 | - SEK | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2023 FY | - SEK | -100.0% |
2023 Q2 | 348.69 Thousand SEK | -56.78% |
2023 Q4 | - SEK | -100.0% |
2023 Q3 | 348.69 Thousand SEK | 0.0% |
2023 Q1 | 806.87 Thousand SEK | -0.13% |
2022 Q4 | 807.93 Thousand SEK | -52.39% |
2022 Q3 | 1.69 Million SEK | -0.17% |
2022 Q2 | 1.69 Million SEK | 0.97% |
2022 Q1 | 1.68 Million SEK | -3.21% |
2021 Q1 | 1.82 Million SEK | 0.0% |
2021 Q4 | 1.73 Million SEK | 17.82% |
2021 Q3 | 1.47 Million SEK | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AcuCort AB | -1.09 Million SEK | 100.0% |
AlzeCure Pharma AB (publ) | -2508.00 SEK | 100.0% |
BioGaia AB (publ) | 181.2 Million SEK | 100.0% |
Enzymatica AB (publ) | 11.49 Million SEK | 100.0% |
Enorama Pharma AB (publ) | 4.29 Million SEK | 100.0% |
Gabather AB (publ) | -1772.00 SEK | 100.0% |
Klaria Pharma Holding AB (publ.) | - SEK | NaN% |
Moberg Pharma AB (publ) | 7.11 Million SEK | 100.0% |
Nanexa AB (publ) | 1.91 Million SEK | 100.0% |
Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | 100.0% |
Orexo AB (publ) | 42.4 Million SEK | 100.0% |
Probi AB (publ) | 116.7 Million SEK | 100.0% |
Swedencare AB (publ) | 398.1 Million SEK | 100.0% |
Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 100.0% |
Toleranzia AB | -1.34 Million SEK | 100.0% |
Vivesto AB | - SEK | NaN% |